Trial of Terbutaline for the Treatment of Status Asthmaticus in Children
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00124995
Recruitment Status :
First Posted : July 29, 2005
Last Update Posted : February 15, 2013
Connecticut Children's Medical Center
Information provided by (Responsible Party):
Christopher Carroll, MD, Connecticut Children's Medical Center
Although widely used for the treatment of pediatric status asthmaticus, intravenous terbutaline has potentially significant side effects; may not improve outcomes; and may increase Intensive Care Unit (ICU) length of stay. This study is designed to test the efficacy of intravenous terbutaline for the treatment of status asthmaticus by adding intravenous terbutaline or placebo to standard asthma treatment. The dose of terbutaline or placebo will be titrated according to severity of illness as quantified by a validated clinical asthma score. Differences in outcomes between the study groups, such as length of stay, hospital costs, and lung function will be compared.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 18 Years (Child, Adult)
Sexes Eligible for Study:
Admission to the Connecticut Children's Medical Center (CCMC) Pediatric Intensive Care Unit (PICU) with a primary admission diagnosis of status asthmaticus
Modified Pulmonary Index Score (MPIS) of greater than or equal to 12
Age between birth and 18 years old
Pre-existing cardiac or pulmonary disease
Existing respiratory failure (requiring invasive or non-invasive mechanical ventilation)
Hemodynamic or cardiovascular instability requiring inotropic support
The patient meets one of the criteria for withdrawal from the study due to patient safety concerns